Sym-024 is under clinical development by Symphogen and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sym-024’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sym-024 is under development for the treatment of advanced or metastatic solid tumors including head and neck squamous cell carcinoma, cervical carcinoma (CC), non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma, colorectal carcinoma, gastric cancer, esophageal squamous cell carcinoma and malignant pleural mesothelioma. The therapeutic candidate is being developed based on Symplex platform technology. It acts by targeting CD73.
Symphogen is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics. The product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), solid tumor malignancies, and lung cancer. It has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and infectious disease area with Genentech. The company has offices in Denmark and New Jersey, the US. Symphogen is headquartered in Ballerup, Denmark.
For a complete picture of Sym-024’s drug-specific PTSR and LoA scores, buy the report here.